• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.

作者信息

He Meijiao, Zhang Yun, Yan Wei, Liu Guangzhong, Sun Danghui, Yuan Yue, Shi Jing, Kong Yihui, Li Yue

机构信息

Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.

Cardiovascular Department, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.

出版信息

Thromb Res. 2020 Jun;190:60-61. doi: 10.1016/j.thromres.2020.03.014. Epub 2020 Mar 19.

DOI:10.1016/j.thromres.2020.03.014
PMID:32304911
Abstract
摘要

相似文献

1
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.60毫克剂量替格瑞洛对中国慢性冠状动脉综合征患者的血小板抑制作用强于氯吡格雷：一项随机、单盲、交叉研究。
Thromb Res. 2020 Jun;190:60-61. doi: 10.1016/j.thromres.2020.03.014. Epub 2020 Mar 19.
2
Effect of ticagrelor and clopidogrel on platelet aggregation function after percutaneous coronary intervention in patients with acute coronary syndrome.替格瑞洛和氯吡格雷对急性冠状动脉综合征患者经皮冠状动脉介入治疗后血小板聚集功能的影响。
J Biol Regul Homeost Agents. 2019;33(2):439-445.
3
Comparison of Antiplatelet Effects and Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Chinese Patients With Acute Coronary Syndrome.替格瑞洛与氯吡格雷在中国急性冠脉综合征患者中抗血小板作用及临床结局的比较
Am J Ther. 2022;29(5):e606-e608. doi: 10.1097/MJT.0000000000001190. Epub 2020 May 12.
4
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
JAMA. 2021 Mar 2;325(9):890. doi: 10.1001/jama.2020.26020.
5
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.在经皮冠状动脉介入治疗后急性冠脉综合征患者的早期和晚期转换为氯吡格雷的疗效和安全性。
Platelets. 2020;31(3):337-343. doi: 10.1080/09537104.2019.1609668. Epub 2019 May 1.
6
Risk of ticagrelor versus clopidogrel discontinuation.
Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):356. doi: 10.1016/j.rec.2023.11.018. Epub 2024 Jan 16.
7
Risk of ticagrelor versus clopidogrel discontinuation. Response.
Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):356-357. doi: 10.1016/j.rec.2023.11.015. Epub 2024 Jan 12.
8
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.替格瑞洛与氯吡格雷对行经皮冠状动脉介入治疗的急性冠状动脉综合征患者主要不良冠状动脉事件的影响。
JAMA Intern Med. 2020 Mar 1;180(3):420-428. doi: 10.1001/jamainternmed.2019.6447.
9
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.替格瑞洛、普拉格雷或氯吡格雷对血管内皮功能和其他血管生物标志物的影响：一项随机交叉研究。
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24.
10
Derivation and Evaluation of the Ischemic Risk Model in High-Risk Chinese Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.高危人群行经皮冠状动脉介入治疗急性冠状动脉综合征的缺血风险模型的推导与评估。
Clin Ther. 2019 Apr;41(4):754-765. doi: 10.1016/j.clinthera.2019.03.001. Epub 2019 Mar 29.